Cefoperazone

Quick links to important sections

Cefoperazone

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefoperazone

What is Cefoperazone? (Overview)

Property Description
Active Ingredient (INN) Cefoperazone (as Cefoperazone Sodium)
Form Sterile powder for reconstitution (Prescription Drug, Rx)
Pharmacological Class Third-Generation Cephalosporin Antibiotic
General Use Treating moderate to severe bacterial infections
Origin Semi-synthetic

What Type of Antibiotic is Cefoperazone?

Cefoperazone is a semi-synthetic, broad-spectrum antibiotic that belongs to the third-generation cephalosporin pharmacological class. The drug is chemically related to penicillin but is structurally modified to enhance its stability and effectiveness. The term semi-synthetic confirms the substance is partly manufactured, derived from the natural Acremonium fungus.

Its third-generation status and unique chemical structure give Cefoperazone clinically recognized activity against certain difficult-to-treat Gram-negative organisms, including Pseudomonas aeruginosa. This makes the medicine specifically useful against resilient bacteria that often cause severe hospital-acquired infections or are resistant to common first-line antibiotics.


Composition and General Therapeutic Purpose

The medicine is supplied as Cefoperazone Sodium, a sterile powder that must be dissolved in liquid prior to administration. This form is necessary because Cefoperazone is poorly absorbed through the digestive tract; therefore, it is exclusively a parenteral drug, administered via injection or intravenous (IV) infusion to achieve the high drug concentrations needed to fight severe infections.

The general therapeutic purpose of Cefoperazone is to resolve a wide spectrum of moderate to severe bacterial infections throughout the body. Its mechanism is bactericidal—it actively kills bacteria by interfering with their cell wall synthesis. It plays a role in managing severe, complicated infections where antibiotic resistance is a concern.

What side effects are possible with Cefoperazone?

Possible Side Effects and Safety Information

The safety profile for Cefoperazone is derived strictly from government regulatory documentation, detailing known adverse reactions and safety restrictions.

Adverse Reactions

Side effects are classified by their frequency and the body systems affected. The most frequently documented reactions (Common, occurring in 1 out of 10 to 1 out of 100 people) are diarrhea and localized injection site reactions.

Less frequent adverse reactions (Uncommon) include pruritus (itching) and urticaria (hives).

Serious and Clinically Significant Risks

Regulatory warnings highlight the potential for severe adverse events, many of which have a frequency of Not Known (cannot be estimated from available data) but are considered clinically significant:

  • Serious Hypersensitivity: Immediate and severe allergic reactions, including anaphylactic shock (which can be fatal), are documented. Caution is required in patients with a known allergy to penicillin or other cephalosporins.
  • Bleeding and Hematologic Disorders: Cases of hemorrhage (bleeding) and hypoprothrombinemia (reduced blood clotting ability) are noted, particularly with prolonged use or in patients with vitamin K deficiency.
  • Gastrointestinal Complications: Severe diarrhea may be indicative of pseudomembranous colitis or Clostridium difficile-associated diarrhea (CDAD), which can occur even after treatment is stopped.
  • Severe Skin Reactions: Serious skin conditions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported.

Population-Specific Safety Considerations

Specific caution and monitoring are noted for patients with combined hepatic (liver) and renal (kidney) dysfunction. Due to the way the drug is eliminated from the body, impairment in both organs can lead to increased accumulation in the serum, which may require a modification in the administered amount.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that overdosage of Cefoperazone is expected to produce clinical manifestations that are primarily extensions of the drug’s known adverse reactions. Documented signs of overexposure may include severe gastrointestinal effects such as nausea, vomiting, diarrhea, and upper abdominal pain. The possibility of hematuria (blood in the urine) is also noted as a potential consequence of high drug exposure.

Severe Outcomes and Emergency Action

A major concern described in regulatory labeling is the risk of central nervous system (CNS) toxicity associated with high serum concentrations. This can lead to severe neurological outcomes such as seizures or encephalopathy (altered mental state). This risk is explicitly noted to be higher in specific populations, including patients with renal impairment, pre-existing CNS disease, or advanced age, due to the potential for drug accumulation. Monitoring of serum concentrations may be required in high-risk patients with concurrent hepatic and renal insufficiency.

Immediate medical help is required if signs of a severe reaction or overexposure are observed. Regulatory authorities mandate that serious anaphylactic reactions—a life-threatening outcome—require immediate emergency treatment. Such mandated interventions include the administration of epinephrine, oxygen, intravenous steroids, and professional airway management. The general management protocol is supportive, focusing on the discontinuation of the agent, and haemodialysis may be performed to enhance the elimination of the drug from the body if overdosage occurs.

Therapeutic Uses of Cefoperazone

What Cefoperazone treats: Main Uses and Benefits

Cefoperazone is commonly used in situations involving certain distressing symptoms of severe bacterial infections where the patient is experiencing symptoms related to heightened physiological stress and systemic imbalance. Commonly treated conditions include septicemia, severe bacterial pneumonia (lower respiratory tract infections), and complex intra-abdominal infections like peritonitis. The medication is relevant for managing symptoms of systemic imbalance, such as persistent high fever and chills, and is applied across domains where additional symptomatic support is needed.

The drug is considered relevant in clinical settings that involve acute or unstable symptom patterns caused by resilient bacteria, such as Pseudomonas aeruginosa. The medication plays a role in managing these systemic manifestations and may assist with maintaining a sense of stability during difficult episodes. Furthermore, Cefoperazone is commonly used in clinical settings that involve acute or unstable symptom patterns as a form of prophylaxis (prevention) for patients undergoing major surgical procedures, which may help with maintaining functional stability and support general well-being during symptomatic phases.


Quick Fact: Relief for Systemic Discomfort Cefoperazone is commonly used in clinical settings that involve acute or unstable symptom patterns, such as those that create noticeable physiological strain in patients with severe infections. Its use in these conditions helps address symptom clusters that may become intense or disruptive.

Eligibility and Restrictions for Use

Cefoperazone eligibility is strictly defined by regulatory authorities based on allergy status, organ function, and age, without clinical interpretation or advice.


Contraindicated Populations

The medicine is contraindicated for any patient with a history of hypersensitivity to Cefoperazone or to any other beta-lactam antibiotics, including penicillins or other cephalosporins. This reflects a mandatory exclusion due to the risk of severe allergic cross-reaction.


Age and Population Restrictions

Cefoperazone is primarily approved for adult patients. Its safety and efficacy have not been established in the pediatric population (children and infants). Use in older adults is permitted but requires caution, as age-related decreases in organ function may necessitate monitoring.


Conditions Requiring Restricted Use

Use is restricted and requires caution and monitoring in patients with severe hepatic dysfunction (liver impairment) or biliary obstruction due to the drug’s primary excretion pathway. Close observation is also required for patients with combined hepatic and renal impairment. Furthermore, patients with coagulopathy risk factors, such as Vitamin K deficiency or malabsorption conditions, require monitoring of clotting status. For pregnant and breastfeeding individuals, no adequate studies exist, and use is only permitted if the potential benefit justifies the documented risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug and drug-substance interaction patterns for Cefoperazone, primarily affecting pharmacokinetic clearance and pharmacodynamic outcomes.

Documented Interaction Patterns

Interaction Partner Official Regulatory Outcome
Alcohol / Ethanol Contraindicated Combination due to the risk of a severe disulfiram-like reaction (flushing, headache).
Probenecid Results in increased and prolonged plasma concentrations of Cefoperazone by inhibiting renal excretion.
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding (hemorrhage) due to potential for additive effects on blood clotting factors (hypoprothrombinemia).
Aminoglycoside Antibiotics Co-administration may result in additive effects and requires monitoring.

Administration Restrictions

Ingestion of alcohol or alcohol-containing products is strictly prohibited during treatment and for a period of up to 72 hours following the final dose of Cefoperazone to prevent the severe disulfiram-like reaction. This mandatory timing rule is a key constraint in the official interaction profile. Furthermore, the drug's primary elimination route is via the bile; therefore, patients with hepatic impairment or biliary obstruction may experience reduced clearance, leading to drug accumulation, a population-specific interaction consideration.

Mechanism of Action

Cefoperazone exerts a bactericidal effect through a mechanism specific to disrupting the integrity of the microbial cell wall. Cefoperazone functions as an irreversible covalent inhibitor of bacterial Penicillin-Binding Proteins (PBPs), a group of enzymes essential for the final cross-linking of the peptidoglycan polymer. This molecular inhibition halts the assembly, preventing the completion of the rigid peptidoglycan structure. The blockade of peptidoglycan cross-linking renders the growing bacterial cell wall structurally incomplete. This defect causes the cell to be unable to withstand its own high internal osmotic pressure, leading to the activation of bacterial autolytic enzymes and immediate, catastrophic cell lysis. When combined with Sulbactam, the mechanism is protected. Sulbactam acts as a suicide inhibitor against bacterial beta-lactamase enzymes, which would otherwise destroy Cefoperazone. This protective action allows the primary PBP inhibition mechanism to function against bacteria that have developed this form of hydrolytic resistance.

Dosage and Administration Information

How to Use Cefoperazone

Cefoperazone is strictly a parenteral medication supplied as a sterile powder for reconstitution, meaning it must be dissolved in a fluid before use. It is never taken by mouth. The official administration routes are Intravenous (IV) infusion or Intramuscular (IM) injection. The method of use is defined by specific official instructions governing dose, frequency, and preparation.


Official Administration and Dosing

Feature Official Labeled Instruction
Route of Administration Exclusively Intravenous (IV) infusion or Intramuscular (IM) injection.
Standard Dosing Schedule (Adults) A usual adult dose ranges from 2 to 4 grams (g) daily, often split into divided doses. For severe or refractory infections, the dose may increase up to 16 g daily in highly supervised settings.
Frequency Pattern Administered in equally divided doses most commonly every 12 hours.
Preparation The sterile powder must be reconstituted with an approved diluent (e.g., sterile water or saline).
IV Infusion Time Typically administered over a period ranging from 15 minutes to one hour.

Population-Specific Use

Special limitations are required for patients with impaired liver function or biliary obstruction, as the drug is primarily eliminated through bile. For these patients, the maximum daily dose is generally restricted to 4 grams of Cefoperazone per day. Dosage for children and neonates is calculated based on body weight and age, with neonates in the first week of life typically receiving the drug every 12 hours. Therapy duration must continue for a minimum of 48 to 72 hours after clinical symptoms of infection have subsided.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefoperazone

Evidence for Severe Intra-Abdominal and Respiratory Infections

Research exploring the clinical evaluation of Cefoperazone, primarily in combination with Sulbactam (a combination agent), has focused on severe bacterial infections like complicated intra-abdominal infections (IAI) and hospital-acquired pneumonia. The available research includes Randomized Controlled Trials (RCTs) and comprehensive systematic reviews, which often assess outcomes alongside active control treatments.

Researchers in these studies focused on several outcomes related to systemic or functional imbalance, including whether the patient achieved clinical stability (meaning researchers tracked the status of clinical stability) and the rate of microbiological eradication (tracking the presence or absence of the causative bacteria). Comparative trials reported measurements of clinical stability that were tracked alongside those seen with active control treatments. However, evidence is limited and findings were mixed regarding specific localized infection sub-sites.

Evidence for Use in High-Risk, Specific Infections

Research has also explored Cefoperazone in combination with Sulbactam for patients facing high-risk, acute conditions. This includes its evaluation in febrile neutropenia and in infections caused by bacteria considered multidrug-resistant (MDR).

For febrile neutropenia, evidence comes mainly from meta-analyses that combine data from multiple RCTs. These studies monitored the overall rate of predefined primary endpoints and all-cause mortality during the acute episode in both adults and children. Research describes patterns observed in these studies where the outcomes were tracked against those seen with active comparator antibiotic treatments.

Research Focused on Multidrug-Resistant Bacteria

The evidence related to specific MDR bacteria, such as Acinetobacter baumannii, relies heavily on observational studies and analyses that look back at patient records. The evidence quality varies across studies, and there is a noted need for more controlled, randomized trials to better characterize the medicine’s profile in this complex setting.

What Remains Uncertain in Cefoperazone Research

One key uncertainty is that the highest quality evidence (RCTs) is almost exclusively for the Cefoperazone/Sulbactam combination, meaning comparative evidence is lacking for Cefoperazone used alone as a monotherapy. Furthermore, studies focusing on short-term outcomes highlight that long-term effects are not fully established. Research has not fully explored the durability of the observed changes or how outcomes related to daily functioning evolved months or years after the initial treatment.

Frequently Asked Questions (FAQ)

Common questions about Cefoperazone (FAQ)


Q: What should I know about Cefoperazone and kidney problems?

Official product information notes that Cefoperazone is mainly eliminated through the bile, meaning its clearance is generally not significantly affected by renal failure alone. Official guidance notes that caution and monitoring are necessary for patients with combined kidney and liver dysfunction, as this can lead to drug accumulation in the body. Furthermore, specific warnings indicate that a serious nervous system condition, encephalopathy, has been reported in patients with pre-existing kidney impairment.


Q: Is Cefoperazone safe to use during pregnancy?

Regulatory documents categorize Cefoperazone in Pregnancy Category B. This means that animal reproduction studies have not demonstrated a risk to the fetus. However, since human data is limited, regulatory documents state that use during pregnancy is permitted only when the potential benefit is judged to outweigh the documented risks.


Q: Can children be treated with Cefoperazone?

Official labeling states that the safety and effectiveness of Cefoperazone have not been fully established in the pediatric population (children and infants). Nevertheless, official documents describe how dosing schedules for children and neonates are calculated, even though safety and efficacy have not been fully established.


Q: What should I tell my doctor before starting Cefoperazone?

Regulatory guidelines describe the conditions requiring disclosure to your healthcare provider, which include any history of allergy to penicillins or other cephalosporin antibiotics. Conditions requiring disclosure also include severe liver disease, kidney disease, bleeding disorders, malabsorption conditions (e.g., Vitamin K deficiency), and a history of colitis or alcohol abuse. Reporting your pregnancy or breastfeeding status is also part of the official guidance prior to treatment initiation.


Q: How long does Cefoperazone stay in your system?

In patients with typical liver function, the mean serum half-life (the time it takes for half the drug to be eliminated) is reported to be approximately 1.7 hours. The half-life may be increased in patients who have liver dysfunction or biliary obstruction, which can lead to higher concentrations of the drug in the body.


Q: Is Cefoperazone an IV medication only?

No, Cefoperazone is strictly a parenteral medication, meaning it cannot be taken by mouth. Official administration routes include both Intravenous (IV) infusion (into a vein) and Intramuscular (IM) injection (into a muscle), depending on the required method of delivery.


Q: Can Cefoperazone be used for urinary tract infections (UTIs)?

Official regulatory documents list that Cefoperazone (often when used in combination with Sulbactam) is approved for the treatment of various bacterial infections. These approved uses include both upper and lower urinary tract infections when they are caused by susceptible organisms.


Q: Is Cefoperazone used for skin infections?

Yes, official regulatory documents indicate that Cefoperazone is approved for the treatment of various bacterial infections, which includes skin and soft tissue infections caused by susceptible organisms.


Q: Can Cefoperazone make you feel tired or dizzy?

Dizziness is listed as a potential adverse reaction in regulatory documents. Additionally, more serious nervous system effects, known as encephalopathy (which can include confusion or delirium), have been reported. These effects are particularly noted in patients who have pre-existing kidney impairment.


Q: Does Cefoperazone treat viral infections?

Cefoperazone is classified as an antibiotic, a type of drug specifically designed to kill or slow the growth of bacteria. Therefore, the medicine does not have an indication or documented effectiveness for treating infections caused by viruses.


Q: What does Cefoperazone treat in the lungs?

Official product information indicates that Cefoperazone is used to treat a range of infections caused by susceptible organisms, which includes upper and lower respiratory tract infections.


Q: How often is Cefoperazone usually administered?

Cefoperazone is typically administered in equally divided doses, most commonly every 12 hours. The therapy duration must continue for a minimum of 48 to 72 hours after clinical symptoms of infection have subsided, as described in official guidelines.


Q: Is it common to feel nauseous after Cefoperazone treatment?

Gastrointestinal side effects are listed among the known adverse reactions for Cefoperazone in regulatory documents. These reported effects include nausea and vomiting.


Q: Are there any long-term effects associated with Cefoperazone use?

Research summarized in regulatory overviews indicates that clinical trials have primarily focused on short-term outcomes following treatment. Consequently, the long-term effects of treatment, including the durability of observed changes or effects on daily functioning months or years later, are not fully established.


Q: Is Cefoperazone a good option for hospital-acquired infections?

Official information notes Cefoperazone's activity against certain resilient bacteria, such as Pseudomonas aeruginosa. These characteristics support its use in managing severe infections that are often hospital-acquired or are resistant to more common first-line antibiotics.


Q: What is the risk of antibiotic resistance with Cefoperazone?

Like all antibiotics, Cefoperazone must only be used to treat confirmed bacterial infections to help limit the development of drug-resistant bacteria. When administered in combination with Sulbactam, the Sulbactam component is included specifically to overcome a common form of resistance by protecting Cefoperazone from inactivation by bacterial enzymes.


Q: Is Cefoperazone used outside of the United States?

Yes, Cefoperazone is approved and regulated by government health authorities in many different regions globally. These include regulatory bodies in the European Union (EMA), Canada (Health Canada), Australia (TGA), and Japan (PMDA/MHLW).


Q: Does Cefoperazone cross the blood-brain barrier?

Pharmacological studies cited in regulatory reviews suggest that Cefoperazone does not penetrate the blood-brain barrier as freely as some other antibiotics in its class. This characteristic is relevant to its use in treating infections of the central nervous system.


Q: Are headaches a known side effect of Cefoperazone?

Headaches are not listed as a common stand-alone side effect. However, regulatory warnings note that a headache is a documented symptom of the severe disulfiram-like reaction that can occur if alcohol or alcohol-containing products are consumed during treatment or within 72 hours after the final dose.


Q: What happens if I miss a dose of Cefoperazone?

Patient counseling guides included in the official product information state that the patient must contact their doctor or pharmacist for instructions if a dose of Cefoperazone is missed. No at-home instruction for making up the dose is provided.


Q: Is Cefoperazone used to treat infections in the abdomen?

Yes, official regulatory documents state that Cefoperazone (often combined with Sulbactam) is approved for the treatment of various bacterial infections. These approved uses include conditions such as peritonitis and other intra-abdominal infections caused by susceptible organisms.

How should Cefoperazone be stored and disposed of?

How to Store and Dispose of Cefoperazone?

Cefoperazone is supplied as a sterile dry powder, and its storage and disposal must strictly follow regulatory guidance.

Storage Conditions

Product Form Labeled Requirement
Unopened Powder Store at or below 25°C (77°F). Keep the vial in the original outer carton to protect the contents from light.
Reconstituted Solution For single use only. Stability is strictly time-and-temperature-dependent; discard any unused solution after the official stability period has expired (e.g., 24 hours at room temperature).

Disposal Instructions

Unused or expired medicine should be disposed of via a drug take-back program. If no program is available, the product must be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and thrown into the household trash. The empty vial's label must have all patient-identifying information removed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefoperazone found in:

A-Z Index: